Add us as a preferred source
This month’s medical research roundup from British universities – from trauma care models and blood tests to cutting sepsis antibiotic treatment to treatment for chronic UTIs.
Global study urges rethink of trauma care models in lower-income countries
An international study of nearly 9,000 injury patients across Africa and South Asia has revealed that nearly half died or were left disabled within three months of hospital discharge. Led by experts at the University of Birmingham, the research highlights an urgent need for smarter, locally tailored trauma-care systems across Low- and Middle-Income Countries (LMICs).
Analysing data from 8,858 patients treated across 19 hospitals in Ghana, Pakistan, Rwanda and South Africa, the NIHR-funded study found that 47.6% of participants either died or suffered moderate-to-severe disability within three months. Overall hospital mortality stood at 6.1%, rising to 9.7% post-discharge, while 40.6% lived with long-term disability. Road traffic collisions accounted for 50% of all recorded injuries, with young men predominantly affected.
Crucially, the findings challenge the assumption that Western emergency models can simply be replicated in resource-limited settings. Patients transported by ambulance or rapidly transferred to major trauma hubs did not experience better recovery rates. Researchers noted that without well-coordinated health infrastructure, proper staffing, and accessible post-discharge rehabilitation, heavy investments in ambulance fleets or centralised specialist centres fail to yield better patient outcomes.
“One of our most surprising findings was that measures often assumed to improve outcomes – such as ambulance transport and rapid transfer to major hospitals, which are similar to highly centralised trauma services – were not consistently linked with better recovery or survival. This does not mean that ambulances cause worse outcomes but suggests that investment in ambulance systems alone is unlikely to improve outcomes unless services are coordinated and appropriately resourced,” said lead author Justine Davies, professor of global health research at the University of Birmingham.
AI model detects signs of faulty DNA repair in ovarian cancer
An artificial intelligence model developed by researchers at King’s College London can identify signs of impaired DNA repair in ovarian cancer cells from standard tissue images. The study demonstrates that the tool could offer a low-cost, widely accessible diagnostic alternative to conventional genomic testing, helping clinicians rapidly match patients with targeted therapies.
The research focused on high-grade serous tubo-ovarian carcinoma (HGSOC), an aggressive form of cancer often characterised by homologous recombination deficiency (HRD). Cancers with HRD have an impaired ability to repair damaged DNA, making them particularly vulnerable to platinum-based chemotherapy and PARP inhibitors. While HRD serves as a crucial biomarker for determining treatment efficacy, standard diagnostic approaches require complex genetic sequencing that can be expensive, time-consuming, and difficult to access in lower-resource settings.
To address this barrier, the team developed an AI architecture named HRDPath. Trained on digital microscopic slides from patients with known molecular profiles, the model analyses cellular organisation and structural features – such as rounder cell nuclei and densely packed cancer cells – to detect HRD. HRDPath correctly identified 91% of HRD-positive cases when evaluating multiple tissue images per patient. If validated in larger clinical cohorts, the tool could enable hospitals to determine treatment eligibility directly from routine diagnostic biopsies.
“We are unlocking information hidden in microscopic images of cancer tissue that could transform how we match patients to treatments. By using AI to reveal defects in DNA repair, we could make precision cancer medicine faster, more affordable and accessible to more women with ovarian cancer, not just in the UK but around the world,” said Heba Sailem, reader in computational pathology at King’s College London.
Dundee trial tests precision medicine approach for Parkinson’s disease
An international clinical trial co-led by researchers at the University of Dundee is evaluating whether a precision medicine approach could slow or halt the progression of Parkinson’s disease. The NEULARK trial is exploring targeted therapies specifically designed for patients with genetic mutations in the LRRK2 protein kinase, which represents the most common inherited cause of the condition.
Parkinson’s disease affects more than 150,000 people across the UK, yet there are currently no approved therapies capable of altering disease trajectory. Researchers at the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU) at Dundee have spent years looking at the structure and function of LRRK2. In a subset of patients, genetic variants cause this master enzyme to become hyperactive, driving cellular dysfunction and progressive neurodegeneration.
Sponsored by Neuron23, the Phase 2 trial is enrolling participants whose genetic profiles indicate elevated LRRK2 activity. Rather than applying a one-size-fits-all model, the trial tests an investigational oral therapy that selectively inhibits the overactive enzyme. Researchers hope that tailoring disease-modifying therapies to specific biological subtypes will yield more effective clinical outcomes for patients living with genetically driven forms of the disease.
“Parkinson’s is not the same disease in everyone. People have different symptoms, the rate of progression changes, and I think what we are now understanding increasingly is that there’s a vast difference in the underlying disease biology for people,” said Esther Sammler, trial lead and consultant neurologist at the University of Dundee. “That really matters because if you have a particular treatment that targets one disease mechanism, then this may be relevant for some, but not for all people with Parkinson’s disease. That is what personalised medicine is,” she added.
Routine blood test could safely cut sepsis antibiotic treatment
A simple daily blood test monitoring a biomarker called procalcitonin (PCT) could help critically ill sepsis patients safely discontinue antibiotics sooner, curbing unnecessary drug exposure and helping combat global antimicrobial resistance. The NIHR-funded study led by researchers at the University of Manchester and Northern Care Alliance NHS Foundation Trust evaluated treatment protocols across 2,760 patients in 41 intensive care units.
Because doctors are naturally cautious about stopping treatment prematurely in severely ill individuals, patients frequently receive prolonged courses of broad-spectrum antibiotics. However, excessive antibiotic use fuels resistant pathogens, increases adverse drug side effects, and heightens healthcare costs.
The ADAPT-Sepsis trial evaluated how clinicians responded to daily automated advice based on blood test results. Researchers found that PCT-based guidance generated recommendations to halt antibiotics nearly two days earlier than guidance using C-reactive protein (CRP), a traditional inflammatory marker that aligns more closely with standard multi-day prescribing habits. Analysing more than 17,000 blood samples, the study demonstrated that biomarker-guided decisions provide a reliable tool for safely shortening treatment duration.
“For decades, intensive care doctors have faced an impossible balancing act. Nobody wants to stop antibiotics too early and risk a patient’s life, but continuing them unnecessarily also carries real dangers for individuals and society,” said Paul Dark, vice dean for health and care partnerships at The University of Manchester and professor of critical care medicine at the Northern Care Alliance NHS Foundation Trust. “What our study shows is that simple biomarker tests can provide an additional layer of reassurance when making these difficult decisions,” he added.
Clinical trial evaluates extended antibiotic therapy for chronic UTIs
A new clinical trial led by University College London (UCL) will investigate whether an extended course of higher-dose antibiotics is safe and effective for treating women with chronic urinary tract infections (UTIs). Funded by the Medical Research Council, the Extended Antibiotic Treatment for UTI Patients (EAT-UP) trial aims to evaluate whether intensifying antimicrobial therapy alongside a urinary antiseptic offers better clinical outcomes than standard NHS treatment options.
Recurrent and chronic UTIs disproportionately affect post-menopausal women, causing persistent pain, urgent urination, and significant morbidity. While recurrent UTIs consist of separate, distinct episodes of infection, chronic UTIs involve a continuous bacterial infection embedded within the bladder wall. Standard NHS guidance often manages chronic cases using low-dose preventative antibiotics or methenamine hippurate, a non-antibiotic antiseptic. However, these regimens frequently fail to clear underlying infections, leaving patients with ongoing symptoms that standard urine dipsticks and cultures often fail to detect.
The EAT-UP trial, led by researchers at the UCL Eastman Dental Institute and the UCL Division of Medicine, is recruiting women with chronic symptoms for a three-month comparative study. Participants are randomly assigned to receive either higher-dose therapeutic antibiotics combined with methenamine hippurate or standard preventative care. Researchers will monitor symptom resolution, infection levels, and safety outcomes over several months to determine whether NHS management guidelines should be updated.
“Extended antibiotic treatment for chronic UTIs is one of the most debated questions in this field. As clinicians and patients hold strong views on both sides, a proper randomised trial with safety monitoring is the best way to investigate the most effective approach to treating women living with these conditions,” said Rajvinder Khasriya, trial lead at the UCL Eastman Dental Institute.
Mental health benefits of education vary between rich and poor nations
Higher levels of education are strongly associated with better mental health in low- and middle-income countries, but provide no significant mental health advantage in high-income nations, according to a cross-national study led by Nottingham Business School at Nottingham Trent University.
The research suggests that education protects mental health primarily by securing access to basic material necessities rather than acting as a direct psychological buffer.
Researchers analysed data from over 120,000 individuals across 121 countries – comprising 42 high-income and 79 low- and middle-income nations – using the Lloyd’s Register Foundation World Risk Poll. In lower-income regions, individuals with secondary or tertiary education were significantly less likely to experience severe mental health issues compared to those with lower educational attainment. However, in wealthier countries where basic infrastructure is broadly accessible regardless of schooling, the statistical association between education level and reduced mental health strain disappeared.
The authors note that in developed nations, the protective benefit of higher education may be offset by workplace pressures, overeducation, and mismatches between career expectations and employment realities. The team argues that interventions must look beyond educational attainment to address the fundamental social and economic drivers of psychological distress.
“Better mental health is not simply about better education. Our findings suggest that education is acting as a pathway to other protective factors, rather than being the direct cause of better mental health. Therefore, increasing educational attainment alone is unlikely to reduce mental health inequalities, and policymakers need to focus more closely on the wider conditions in which people live and work,” said Christopher Lalley, co-author of the study and lecturer in economics at Nottingham Business School.
